# Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

> **NCT01970488** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 350 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Adalimumab
- **BIOLOGICAL:** ABP 501

## Key facts

- **NCT ID:** NCT01970488
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-18
- **Primary completion:** 2014-08-14
- **Final completion:** 2015-03-18
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970488, "Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01970488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*